Close
Help





JOURNAL

Magnetic Resonance Insights

Gadobutrol in India—A Comprehensive Review of Safety and Efficacy

Submit a Paper


Magnetic Resonance Insights 2017:10 1178623X17730048

Review

Published on 11 Sep 2017

DOI: 10.1177/1178623X17730048


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Magnetic Resonance Insights

Abstract

Gadobutrol is a gadolinium (Gd)-based contrast agent for magnetic resonance imaging (MRI). In India, gadobutrol is approved for MRI of the central nervous system (CNS), liver, kidneys, breast and for MR angiography for patients 2 years and older. The standard dose for all age groups is 0.1 mmol/kg body weight. The safety profile has been demonstrated in 42 clinical phase 2 to 4 studies (>6800 patients), 7 observational studies, and by assessing pharmacovigilance data of 29 million applications. Furthermore, studies in children, adults, and elderly and in patients with impaired liver or kidney function did not show any increased adverse event rate. Diagnostic efficacy was demonstrated in numerous studies and various indications, such as diseases of the CNS, peripheral and supra-aortic vessels, kidneys, liver, and breast.



Downloads

PDF  (1.39 MB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

XML   (111.95 KB XML FORMAT)

BibTex citation   (BIBDESK, LATEX)





Quick Links


New article and journal news notification services